Evidence map›Paper›PMID 36768191›Full record

ArticleInternational journal of molecular sciences2023

Discrimination between Complete versus Non-Complete Pathologic Response to Neoadjuvant Therapy Using Ultrasensitive Mutation Analysis: A Proof-of-Concept Study in

Anna P Sokolenko, Fedor V Moiseyenko, Aglaya G Iyevleva, Alexandr O Ivantsov, Georgiy D Dolmatov, Ksenia V Shelekhova, Elizaveta V Gulo, Anastasya X Topal, Elizaveta V Artemieva, Nuriniso H Abduloeva and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Recent Advances in Breast Cancer Research.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anna P SokolenkoDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 Saint Petersburg, Russia.
Fedor V MoiseyenkoCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.ORCID 0000-0003-2544-9042
Aglaya G IyevlevaDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 Saint Petersburg, Russia.
Alexandr O IvantsovDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 Saint Petersburg, Russia.
Georgiy D DolmatovCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Ksenia V ShelekhovaCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.ORCID 0000-0002-2113-0053
Elizaveta V GuloCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Anastasya X TopalCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Elizaveta V ArtemievaCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Nuriniso H AbduloevaCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Nikita A RysevCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Daria A BarsovaCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Natalia V LevchenkoCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Nikita M VolkovCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Vitaliy V EgorenkovCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Vladimir M MoiseyenkoCity Cancer Center, 68A Leningradskaya Street, Pesochny, 197758 Saint Petersburg, Russia.
Evgeny N ImyanitovDepartment of Tumor Growth Biology, N.N. Petrov Institute of Oncology, 197758 Saint Petersburg, Russia.ORCID 0000-0003-4529-7891

Funding

Russia Science Foundation 22-15-00266
6 · The paper itself

Abstract

Neoadjuvant chemotherapy (NACT) for breast cancer (BC) often results in pathologic complete response (pCR), i.e., the complete elimination of visible cancer cells. It is unclear whether the use of ultrasensitive genetic methods may still detect residual BC cells in complete responders. Breast carcinomas arising in

Indexed as

Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinFemaleHumansMutationNeoadjuvant TherapyBRCA1 ProteinBRCA1 protein, humanBRCA1 mutationbreast cancerneoadjuvant chemotherapypathologic complete responsereview

Identifiers

PMID36768191
PMCPMC9914941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.